A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by "Lying-Sitting-Standing" Sequential Baduanjin
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: standard treatment and routine rehabilitation nursing guidance, "Lying-Sitting-Standing" Sequential Baduanjin.
- Who it may be relevant to
- Registry conditions: ACS (Acute Coronary Syndrome), HF - Heart Failure. Basic parameters: up to 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure
Interventions
- Behavioral standard treatment and routine rehabilitation nursing guidance
standard treatment and routine rehabilitation nursing guidance - Behavioral "Lying-Sitting-Standing" Sequential Baduanjin
"Lying-Sitting-Standing" Sequential Baduanjin
Primary outcome measures
- Patients were stratified based on their 6-minute walk test distance [Time frame: From enrollment to the end of the 12-week treatment]
- NYHA（New York Heart Association）classification of cardiac function [Time frame: From enrollment to the end of the 12-week treatment]
- Left ventricular ejection fraction (LVEF) on echocardiography [Time frame: From enrollment to the end of the 12-week treatment]
- C-reactive protein levels [Time frame: From enrollment to the end of the 12-week treatment]
- ＳＦ-３６（ShortForm36HealthSurvey） [Time frame: From enrollment to the end of the 12-week treatment]
- NT-proBNP（N-terminal pro-B-type natriuretic peptide）levels [Time frame: From enrollment to the end of the 12-week treatment]
- FMD（flow-mediated vasodilation） [Time frame: From enrollment to the end of the 12-week treatment]
- ADL（Activities of Daily Living Scale） [Time frame: From enrollment to the end of the 12-week treatment]
Eligibility criteria
Inclusion criteria
- Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)
- Complicated by heart failure during hospitalization
- Age ≤ 85 years
- Muscle strength ≥ grade 3
- No history of mental illness, conscious and able to cooperate independently with this study
- Voluntarily participate in this study and sign the informed consent form
Exclusion criteria
- Patients with persistent heart failure symptoms or NYHA functional class IV despite optimal pharmacological therapy;
- Patients with contraindications to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;
- Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;
- Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;
- Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;
- Patients with a life expectancy of less than one year;
- Patients currently participating in other clinical trials.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Second Hospital of Shanxi Medical — Taiyuan
Identifiers
NCT: NCT07486791 · SecondShanxiMU01